These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12846401)

  • 41. The resurgence of serum alkaline phosphatase as a surrogate biomarker for prognosis in primary sclerosing cholangitis.
    Talwalkar JA; Chapman RW
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):847-9. PubMed ID: 23591287
    [No Abstract]   [Full Text] [Related]  

  • 42. Bile acids for primary sclerosing cholangitis.
    Chen W; Gluud C
    Cochrane Database Syst Rev; 2003; (2):CD003626. PubMed ID: 12804480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simultaneous occurrence of PSC and MS in a patient.
    Gross JB; Kumar N
    Dig Dis Sci; 2003 Jul; 48(7):1397. PubMed ID: 12870803
    [No Abstract]   [Full Text] [Related]  

  • 44. Treatment of Primary Sclerosing Cholangitis Including Transplantation.
    Wheless WH; Russo MW
    Clin Liver Dis; 2024 Feb; 28(1):171-182. PubMed ID: 37945158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New therapeutic option with N-acetylcysteine for primary sclerosing cholangitis: two case reports.
    Ozdil B; Cosar A; Akkiz H; Sandikci M; Kece C
    Am J Ther; 2011 May; 18(3):e71-4. PubMed ID: 20019586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ursodeoxycholic acid in primary sclerosing cholangitis.
    Triantos CK; Koukias N; Nikolopoulou V; Burroughs AK
    Aliment Pharmacol Ther; 2012 Mar; 35(5):622-3. PubMed ID: 22300127
    [No Abstract]   [Full Text] [Related]  

  • 48. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of autoimmune hepatic diseases].
    Bueverov AO
    Klin Med (Mosk); 2004; 82(10):62-6. PubMed ID: 15584604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Possible recurrence of primary sclerosing cholangitis following living-related liver transplantation: report of a case.
    Kita Y; Lake JR; Ferrell LD; Mori M; Roberts JP; Kakizoe S; Kiyosawa K; Tanaka E; Shiga J; Takikawa H; Inoue Y; Ohtake T; Ohtomo K; Yotsuyanagi H; Oka T; Harihara Y; Takayama T; Kubota K; Kawarasaki H; Hashikura Y; Kawasaki S; Ascher NL; Makuuchi M
    Transplant Proc; 1998 Nov; 30(7):3321-3. PubMed ID: 9838468
    [No Abstract]   [Full Text] [Related]  

  • 51. [Treatment of cholestatic liver diseases].
    Karvonen AL
    Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of primary sclerosing cholangitis.
    Floreani A; De Martin S
    Dig Liver Dis; 2021 Dec; 53(12):1531-1538. PubMed ID: 34011480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
    Tung BY; Emond MJ; Haggitt RC; Bronner MP; Kimmey MB; Kowdley KV; Brentnall TA
    Ann Intern Med; 2001 Jan; 134(2):89-95. PubMed ID: 11177311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [State-of-the-art therapy for primary sclerosing cholangitis].
    Wanger S; Meier PN; Maschek H; Nashan B; Manns MP
    Dtsch Med Wochenschr; 1998 Mar; 123(11):325-7. PubMed ID: 9540772
    [No Abstract]   [Full Text] [Related]  

  • 55. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis.
    Ashraf I; Choudhary A; Arif M; Matteson ML; Hammad HT; Puli SR; Bechtold ML
    Indian J Gastroenterol; 2012 Apr; 31(2):69-74. PubMed ID: 22528343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
    Hay JE
    Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series.
    Schramm C; Schirmacher P; Helmreich-Becker I; Gerken G; zum Büschenfelde KH; Lohse AW
    Ann Intern Med; 1999 Dec; 131(12):943-6. PubMed ID: 10610645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Recent progress in the diagnosis and therapy of autoimmune hepatitis].
    Zenia M; Toda G
    Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1763-7. PubMed ID: 10581761
    [No Abstract]   [Full Text] [Related]  

  • 59. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.
    Charatcharoenwitthaya P; Lindor KD
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):32-6. PubMed ID: 17234554
    [No Abstract]   [Full Text] [Related]  

  • 60. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
    Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
    Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.